Boehringer and Envisagenics to develop precision cancer therapies in $1bn deal
Boehringer Ingelheim and Envisagenics have entered into a research collaboration and option agreement aimed at validating tumour-specific targets for the development of precision therapies in solid tumours.
Read the full article on the original site.
Read Full Article